Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Ulcerative Colitis
Sort By
Newest First
1 / 1
1 / 1
Clinical Trials
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
Theravance Biopharma, Inc.
PR-M03-19-NI-035
Mar 13, 2019
Final Results
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
Protagonist Therapeutics
PR-M08-18-NI-055
Aug 14, 2018
FDA Approval
Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
Pfizer
PR-M06-18-NI-012
Jun 05, 2018
